---
title: "Key facts: Esperion to Delist from Nasdaq; Merger Creates $100M CVR"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292581403.md"
description: "Esperion Therapeutics (ESPR) said on July 13, 2026 it will delist from Nasdaq after its merger, submitting Form 25; ESPR shares will stop trading on Nasdaq and it will file Form 15. 1Esperion Therapeutics (ESPR) completed its merger July 13, 2026, creating up to $100 million in milestone CVR payments; Essence Parent is counterparty and Computershare is rights agent. 2"
datetime: "2026-07-14T07:13:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292581403.md)
  - [en](https://longbridge.com/en/news/292581403.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292581403.md)
generator: "portal-rs"
---

# Key facts: Esperion to Delist from Nasdaq; Merger Creates $100M CVR

-   Esperion Therapeutics (ESPR) said on July 13, 2026 it will delist from Nasdaq after its merger, submitting Form 25; ESPR shares will stop trading on Nasdaq and it will file Form 15. 1
-   Esperion Therapeutics (ESPR) completed its merger July 13, 2026, creating up to $100 million in milestone CVR payments; Essence Parent is counterparty and Computershare is rights agent. 2

### Related Stocks

- [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md)
- [CPU.AU](https://longbridge.com/en/quote/CPU.AU.md)

## Related News & Research

- [Esperion Therapeutics Closes Merger; Sets $100M CVR Plan, Amends 2030 Notes, Replaces Credit Facility](https://longbridge.com/en/news/292494712.md)
- [Esperion acquired in cash-and-CVR merger transaction](https://longbridge.com/en/news/292521304.md)
- [Wrap Technologies (NASDAQ: WRAP) Selected to Support Florida Teacher Safety Training Program](https://longbridge.com/en/news/296129490.md)
- [Annita Tanini Sells 1,224 Shares of Keros Therapeutics (NASDAQ:KROS) Stock](https://longbridge.com/en/news/296537997.md)
- [Archimed completes take-private of Esperion in deal valued up to $1.1 billion](https://longbridge.com/en/news/292496629.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**